a kinase of the PLK family. Contains a polo-box domain (PBD), a specific phosphoserine or phosphothreonine binding domain. Substrates include BRCA2, Myt1, NudC, Cdc25C, cyclin B1, Nlp and other mitotic proteins. Inhibited by ATR. Plays a role in regulation of cytokinesis and coordinating M-phase events. Note: This description may include information from UniProtKB.
Protein type: Kinase, protein; EC 184.108.40.206; Protein kinase, Ser/Thr (non-receptor); Protein kinase, Other; Other group; PLK family
Molecular Function: protein serine/threonine kinase activity; protein binding; microtubule binding; kinase activity; protein kinase binding; ATP binding; protein kinase activity
Biological Process: positive regulation of ubiquitin-protein ligase activity during mitotic cell cycle; positive regulation of proteolysis; regulation of cell cycle; regulation of mitotic cell cycle; mitotic nuclear envelope disassembly; anaphase-promoting complex activation during mitotic cell cycle; protein ubiquitination; cytokinesis; negative regulation of transcription from RNA polymerase II promoter; protein amino acid phosphorylation; response to antibiotic; establishment of protein localization; cytokinesis after mitosis; anaphase-promoting complex-dependent proteasomal ubiquitin-dependent protein catabolic process; centrosome organization and biogenesis; positive regulation of ubiquitin-protein ligase activity; mitotic cell cycle spindle assembly checkpoint; G2/M transition of mitotic cell cycle; mitosis; mitotic sister chromatid segregation; protein destabilization; regulation of mitotic metaphase/anaphase transition; negative regulation of cyclin-dependent protein kinase activity; cell proliferation; peptidyl-serine phosphorylation; regulation of ubiquitin-protein ligase activity during mitotic cell cycle; positive regulation of proteasomal ubiquitin-dependent protein catabolic process; regulation of protein binding; polar body extrusion after meiotic divisions; mitotic cell cycle; G2/M transition DNA damage checkpoint; mitotic metaphase/anaphase transition; microtubule bundle formation; negative regulation of apoptosis
SS: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.